GRFS peer analysis
Grifols (GRFS) against its competitors: price, today's move, 1-year return and market value side by side.
GRFS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ABT Abbott | $110.16 | 3.73% | -10.89% | $183.77B |
| ADMA ADMA Biologics | $11.06 | -3.07% | -28.55% | $2.56B |
| BDX Becton Dickinson | $198.60 | 0.36% | 11.13% | $53.90B |
| BIO Bio-Rad | $366.16 | -1.62% | 14.59% | $9.95B |
| HAE Haemonetics | $120.14 | 0.41% | 140.23% | $5.44B |
| MRVI Maravai LifeSciences | $7.19 | -7.94% | 128.98% | – |
| QDEL QuidelOrtho | $14.03 | 5.89% | -48.02% | $908.62M |
| TECH Bio-Techne | $72.67 | 0.01% | 16.14% | $11.41B |
| GRFS Grifols | $8.51 | 5.06% | -9.18% | $5.51B |
- GRFS's peers: ABT (Abbott), ADMA (ADMA Biologics), BDX (Becton Dickinson), BIO (Bio-Rad), HAE (Haemonetics), MRVI (Maravai LifeSciences), QDEL (QuidelOrtho), TECH (Bio-Techne).
Updated 2026-11-03 12:34 UTC